Daratumumab combination prolongs myeloma survival.
Manjulika
M
Das
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D000074322:Antineoplastic Agents, Immunological / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D018572:Disease-Free Survival; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality / Q000473:pathology; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D013997:Time Factors; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D000074322:Antineoplastic Agents, Immunological; C556306:daratumumab